Analysis of Biotech Securities Class Action Motion to Dismiss Decisions, 2005-2022
Five years ago, we surveyed a decade’s worth of federal district court decisions on motions to dismiss securities claims brought against development-stage biotech companies to answer an important question: are these cases more likely to…
